KNSA
Kiniksa Pharmaceuticals, Ltd. · Healthcare
48.84
1.44%(-0.71)
Market OpenLast Updated: — ET
52W L: $18.2552W H: $50.03
$48.73
CHG+3.49 (+7.71%)
H$56.43
L$43.02
VOL9.5M
KNSA (1h)
Kiniksa Pharmaceuticals, Ltd. · Healthcare
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA - Get Free Report) hit a new 52-week high during mid-day trading on Tuesday. The company traded as high as $50.03 and last traded at $49.55, with a volume of 790616 shares trading hands. The stock had previously closed at $48.82. Analysts Set New Price Targets A number of
Aberdeen Group plc grew its stake in shares of Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) by 152.4% in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 400,598 shares of the company's stock after acquiring an additional 241,876 shares during the quarter.
Top stocks near buy points this week include three lesser-known AI-adjacent plays.
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the nine ratings firms that are presently covering the stock, Marketbeat Ratings reports. Two research analysts have rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average
Kiniksa Pharmaceuticals International (NASDAQ: KNSA) reported fourth-quarter and full-year 2025 results highlighting continued growth for ARCALYST in recurrent pericarditis, a return to profitability, and progress across its clinical pipeline, including its ongoing KPL-387 program and plans to enter the clinic with KPL-1161. ARCALYST revenue growth and 2026 guidance CEO Sanj K. Patel said ARCALYST revenue continued
LONDON, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026 at 3:10 p.m. Eastern Time.
Tessari Eben
officer: CHIEF STRATEGY OFFICER
33,200 SH @ $48.13
2026-04-01
Tessari Eben
officer: CHIEF STRATEGY OFFICER
5,975 SH @ $0.00
2026-04-01
Tessari Eben
officer: CHIEF STRATEGY OFFICER
1,756 SH @ $48.13
2026-04-01
Tessari Eben
officer: CHIEF STRATEGY OFFICER
365 SH @ $24.16
2026-01-15
Tessari Eben
officer: CHIEF STRATEGY OFFICER
16,600 SH @ $0.00
2026-04-01
Tessari Eben
officer: CHIEF STRATEGY OFFICER
8,300 SH @ $0.00
2026-04-01
Tessari Eben
officer: CHIEF STRATEGY OFFICER
2,457 SH @ $0.00
2026-04-01
Tessari Eben
officer: CHIEF STRATEGY OFFICER
1,745 SH @ $0.00
2026-04-01